Literature DB >> 33569984

Dual targeting of toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment.

Laura Kate Gadanec1, Tawar Qaradakhi1, Kristen R McSweeney1, Benazir Ali1, Anthony Zulli1, Vasso Apostolopoulos1.   

Abstract

Entities:  

Keywords:  ACE2; COVID-19; SARS-CoV-2; TLR4; angiotensin-converting enzyme 2; coronavirus; coronavirus disease 2019; toll-like receptor

Year:  2021        PMID： 33569984      PMCID： PMC7885526          DOI： 10.2217/fmb-2021-0018

Source DB:  PubMed          Journal:  Future Microbiol        ISSN： 1746-0913            Impact factor:   3.165


× No keyword cloud information.
  44 in total

1.  Role of human TLR4 in respiratory syncytial virus-induced NF-κB activation, viral entry and replication.

Authors:  Nico Marr; Stuart E Turvey
Journal:  Innate Immun       Date:  2012-04-25       Impact factor: 2.680

2.  The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex.

Authors:  Beom Seok Park; Dong Hyun Song; Ho Min Kim; Byong-Seok Choi; Hayyoung Lee; Jie-Oh Lee
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

Review 3.  DAMP-sensing receptors in sterile inflammation and inflammatory diseases.

Authors:  Tao Gong; Lei Liu; Wei Jiang; Rongbin Zhou
Journal:  Nat Rev Immunol       Date:  2019-09-26       Impact factor: 53.106

4.  Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines.

Authors:  Kol A Zarember; Paul J Godowski
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

5.  Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients.

Authors:  Liting Chen; Xiaolu Long; Qian Xu; Jiaqi Tan; Gaoxiang Wang; Yang Cao; Jia Wei; Hui Luo; Hui Zhu; Liang Huang; Fankai Meng; Lifang Huang; Na Wang; Xiaoxi Zhou; Lei Zhao; Xing Chen; Zekai Mao; Caixia Chen; Zhen Li; Ziyong Sun; Jianping Zhao; Daowen Wang; Gang Huang; Wei Wang; Jianfeng Zhou
Journal:  Cell Mol Immunol       Date:  2020-07-03       Impact factor: 11.530

6.  COVID-19 Severity Correlates with Weaker T-Cell Immunity, Hypercytokinemia, and Lung Epithelium Injury.

Authors:  Zhongfang Wang; Xiaoyun Yang; Yumin Zhou; Jing Sun; Xiaoqing Liu; Jing Zhang; Xinyue Mei; Jiaying Zhong; Jincun Zhao; Pixin Ran
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

7.  Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count.

Authors:  Xiaojie Bi; Zhengxian Su; Haixi Yan; Juping Du; Jing Wang; Linping Chen; Minfei Peng; Shiyong Chen; Bo Shen; Jun Li
Journal:  Platelets       Date:  2020-05-05       Impact factor: 3.862

8.  In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.

Authors:  Abhigyan Choudhury; Suprabhat Mukherjee
Journal:  J Med Virol       Date:  2020-05-17       Impact factor: 2.327

9.  Cell entry mechanisms of SARS-CoV-2.

Authors:  Jian Shang; Yushun Wan; Chuming Luo; Gang Ye; Qibin Geng; Ashley Auerbach; Fang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-06       Impact factor: 11.205

Review 10.  Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.

Authors:  Jin Wang; Mengmeng Jiang; Xin Chen; Luis J Montaner
Journal:  J Leukoc Biol       Date:  2020-06-13       Impact factor: 6.011
View more
  10 in total

1.  Comparison of COVID-19 characteristics in Egyptian patients according to their Toll-Like Receptor-4 (Asp299Gly) polymorphism.

Authors:  Sara I Taha; Aalaa K Shata; Eman M El-Sehsah; Manar F Mohamed; Nouran M Moustafa; Mariam K Youssef
Journal:  Infez Med       Date:  2022-03-01

Review 2.  Toll-Like Receptor Signaling in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Innate Immune Responses and the Potential Application Value of Toll-Like Receptor Immunomodulators in Patients With Coronavirus Disease 2019.

Authors:  Jiayu Dai; Yibo Wang; Hongrui Wang; Ziyuan Gao; Ying Wang; Mingli Fang; Shuyou Shi; Peng Zhang; Hua Wang; Yingying Su; Ming Yang
Journal:  Front Microbiol       Date:  2022-06-27       Impact factor: 6.064

3.  Discovery of diminazene as a dual inhibitor of SARS-CoV-2 human host proteases TMPRSS2 and furin using cell-based assays.

Authors:  Ya-Ming Xu; Marielle Cascaes Inacio; Manping X Liu; A A Leslie Gunatilaka
Journal:  Curr Res Chem Biol       Date:  2022-03-14

4.  Toll-Like Receptor 4 Polymorphisms (896A/G and 1196C/T) as an Indicator of COVID-19 Severity in a Convenience Sample of Egyptian Patients.

Authors:  Sara I Taha; Aalaa K Shata; Shereen A Baioumy; Shaimaa H Fouad; Sherif G Anis; Isis M Mossad; Nouran M Moustafa; Dina M Abdou; Mariam K Youssef
Journal:  J Inflamm Res       Date:  2021-11-27

5.  Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches.

Authors:  Esley S Santos; Priscila C Silva; Paulo S A Sousa; Cristhyane C Aquino; Gabriella Pacheco; Luiz F L S Teixeira; Alyne R Araujo; Francisca B M Sousa; Romulo O Barros; Ricardo M Ramos; Jefferson A Rocha; Lucas A D Nicolau; Jand V R Medeiros
Journal:  Chem Biol Interact       Date:  2022-09-15       Impact factor: 5.168

6.  Diminazene Aceturate Reduces Angiotensin II Constriction and Interacts with the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2.

Authors:  John M Matsoukas; Laura Kate Gadanec; Anthony Zulli; Vasso Apostolopoulos; Konstantinos Kelaidonis; Irene Ligielli; Kalliopi Moschovou; Nikitas Georgiou; Panagiotis Plotas; Christos T Chasapis; Graham Moore; Harry Ridgway; Thomas Mavromoustakos
Journal:  Biomedicines       Date:  2022-07-18

7.  Inhalable Vaccines: Can They Help Control Pandemics?

Authors:  Vivek P Chavda; Lalitkumar K Vora; Vasso Apostolopoulos
Journal:  Vaccines (Basel)       Date:  2022-08-13

Review 8.  Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world.

Authors:  Vivek P Chavda; Qian Yao; Lalitkumar K Vora; Vasso Apostolopoulos; Chirag A Patel; Rajashri Bezbaruah; Aayushi B Patel; Zhe-Sheng Chen
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

9.  COVID-19 Vaccines in the Pipeline, Are Antibodies Adequate?

Authors:  Md Kamal Hossain; Majid Hassanzadeganroudsari; Jack Feehan; Vasso Apostolopoulos
Journal:  Vaccines (Basel)       Date:  2021-03-10

10.  Extracellular Vesicle Associated miRNAs Regulate Signaling Pathways Involved in COVID-19 Pneumonia and the Progression to Severe Acute Respiratory Corona Virus-2 Syndrome.

Authors:  Agnes S Meidert; Stefanie Hermann; Florian Brandes; Benedikt Kirchner; Dominik Buschmann; Jean-Noël Billaud; Matthias Klein; Anja Lindemann; Elisa Aue; Gustav Schelling; Michael W Pfaffl; Marlene Reithmair
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.